Jaguar Health, Inc. - Common Stock (NQ:JAGX)

0.8075 -0.0575 (-6.65%)

Streaming Delayed Price Updated: 3:41 PM EDT, Aug 28, 2026 Add to My Watchlist

Price and Volume

Volume	151,289
Open	0.8560
Bid (Size)	0.7951 (300)
Ask (Size)	0.8050 (500)
Prev. Close	0.8650
Today's Range	0.7950 - 0.8600
52wk Range	0.7250 - 85.40
Shares Outstanding	171,350,166
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

August 26, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Jaguar Health Reports Q2 2026 Results: Full Earnings Call Transcript ↗

August 19, 2026

Jaguar Health (NASDAQ:JAGX) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings...

Via Benzinga

Performance

YTD	-97.7%	-97.7%
1 Month	-16.3%	-16.3%
3 Month	-75.5%	-75.5%
6 Month	-97.3%	-97.3%
1 Year	-98.7%	-98.7%

More News

Jaguar Health Reports Second Quarter 2026 Financials

August 19, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

August 18, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

August 05, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Jaguar Health Compliant with Nasdaq Bid Price Rule

May 27, 2026

Via ACCESS Newswire

Jaguar Health Inc (NASDAQ:JAGX) Swings to Profit on Licensing Deal, But Market Sells the News ↗

May 20, 2026

Via Chartmill

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

July 28, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

July 22, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

What's going on in today's session ↗

July 16, 2026

Via Chartmill

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

June 30, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

June 26, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

June 25, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

June 23, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

June 23, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

June 22, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention

June 18, 2026

From Jaguar Health, Inc.

Via ACCESS Newswire

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

June 12, 2026

Via ACCESS Newswire

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

June 08, 2026

Via ACCESS Newswire

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

May 28, 2026

Via ACCESS Newswire

Jaguar Health (JAGX) Q3 2025 Earnings Transcript ↗

May 21, 2026

Via The Motley Fool

Wondering what's happening in today's after-hours session? ↗

May 20, 2026

Via Chartmill

Jaguar Health Reports First Quarter 2026 Financials

May 20, 2026

Via ACCESS Newswire

Jaguar (JAGX) Q4 2025 Earnings Transcript ↗

May 20, 2026

Via The Motley Fool

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

May 19, 2026

Via ACCESS Newswire

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?

Yes, Jaguar Health, Inc. - Common Stock is publicly traded.

What exchange does Jaguar Health, Inc. - Common Stock trade on?

Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Jaguar Health, Inc. - Common Stock?

The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market

What is the current price of Jaguar Health, Inc. - Common Stock?

The current price of Jaguar Health, Inc. - Common Stock is 0.8075

When was Jaguar Health, Inc. - Common Stock last traded?

The last trade of Jaguar Health, Inc. - Common Stock was at 08/28/26 03:41 PM ET

What is the market capitalization of Jaguar Health, Inc. - Common Stock?

The market capitalization of Jaguar Health, Inc. - Common Stock is 138.37M

How many shares of Jaguar Health, Inc. - Common Stock are outstanding?

Jaguar Health, Inc. - Common Stock has 138M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.